Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
Part of paid clinical trials in Bessemer, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT00313768
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- paclitaxel + carboplatin + bevacizumab — DRUGpaclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
- carboplatin + paclitaxel + bevacizumab + PF-3512676 — DRUGcarboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
Study Details
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Key Dates
- First listed
- Apr 12, 2006
- Start date
- Dec 31, 2005
- Status verified
- Sep 2009
- Primary completion
- May 31, 2008
- Completion
- May 31, 2008
Study Design
- Enrollment
- 23 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: BStandard of care chemotherapy
- Experimental: AStandard of care chemotherapy plus experimental intervention (PF-3512676)
Primary Outcome Measure
Progression-free survival [ Time Frame: 110 Events ]
Locations (29)
Find similar trials in Bessemer, AL
Related Studies
- Molecular Analysis of Thoracic MalignanciesEnrolling By Invitation · Stanford University · Stanford, California
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- Development and Analysis of a Stool Bank for Cancer PatientsRecruiting · Persephone Biosciences · Fountain Valley, California